Amicus Therapeutics, Inc. (FOLD) Holdings Lifted by American International Group Inc.
American International Group Inc. raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 23.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,628 shares of the biopharmaceutical company’s stock after purchasing an additional 20,597 shares during the quarter. American International Group Inc. owned 0.07% of Amicus Therapeutics worth $1,653,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FOLD. Janus Henderson Group PLC acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at about $70,762,000. Farallon Capital Management LLC acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at about $30,210,000. Jennison Associates LLC increased its position in shares of Amicus Therapeutics by 9.4% in the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after acquiring an additional 838,267 shares during the last quarter. FMR LLC increased its position in shares of Amicus Therapeutics by 3.4% in the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock valued at $215,876,000 after acquiring an additional 705,153 shares during the last quarter. Finally, Redmile Group LLC increased its position in shares of Amicus Therapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after acquiring an additional 668,080 shares during the last quarter.
In related news, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the sale, the insider now directly owns 69,184 shares in the company, valued at $940,210.56. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO William D. Baird III sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $570,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 680,437 shares of company stock valued at $9,734,522. Corporate insiders own 3.40% of the company’s stock.
Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $12.98 on Wednesday. Amicus Therapeutics, Inc. has a 1-year low of $4.41 and a 1-year high of $16.60. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same quarter in the prior year, the firm earned ($0.33) EPS. The company’s revenue was up 419.0% on a year-over-year basis. sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Stock Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related stocks with our FREE daily email newsletter.